TISAGENLECLEUCEL
UNII Q6C9WHR03O

Substance Identification & Data

This profile provides standardized clinical and technical data for Tisagenlecleucel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) Q6C9WHR03O.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 1823078-37-0 and the RxNorm Concept ID (RxCUI) 1986438. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

Q6C9WHR03O

CAS Registry Number

1823078-37-0

RxNorm Concept ID

1986438

Detailed Substance Profile

Preferred Name

TISAGENLECLEUCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

Molecular Formula

Q6C9WHR03O

The specific atomic composition represented as a molecular structure string.

NCI Thesaurus

C102758

National Cancer Institute reference terminology for clinical and research data.

INN ID

10557

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

BC-84

Identifier assigned by the United States Adopted Names Council.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Tisagenlecleucel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

TISAGENLECLEUCEL

Common Names & Synonyms

CAR.CD19-REDIRECTED T CELLS

GENE MODIFICATION OF T CELLS IS MEDIATED BY STABLE INSERTION VIA TRANSDUCTION WITH A SELF-INACTIVATING, REPLICATION-DEFICIENT LENTIVIRAL (LV) VECTOR CONTAINING THE CTL019 TRANSGENE UNDER THE CONTROL OF THE EF-1 ALPHA PROMOTER. THE DRUG PRODUCT IS A MIXTURE OF TRANSGENE POSITIVE AND NEGATIVE T CELLS THAT ARE DELIVERED TO THE PATIENT ON THE BASIS OF PERCENT TRANSGENE POSITIVE T CELLS.

TISAGENLECLEUCEL [INN]

TISAGENLECLEUCEL [USAN]

TISAGENLECLEUCEL [WHO-DD]

TISAGENLECLEUCEL-T